文献速递神经肿瘤

PIK3R2免疫染色状态预测新诊断胶质母细胞瘤自体肿瘤疫苗治疗患者的预后

PIK3R2 immunostaining status predicts prognosis in patients with newly diagnosed glioblastoma treated with an autologous tumor vaccine.
PubMed 文献 · J Neurooncol · 2025-06-12

本研究分析58例新诊断IDH野生型GBM或IDH突变型4级星形细胞瘤患者,其中29例接受标准治疗联合自体福尔马林固定肿瘤疫苗(AFTV),29例仅接受标准治疗。免疫染色检测PIK3R2和p53,以34%为PIK3R2阳性 cutoff 值。AFTV组中PIK3R2阴性者生存期较对照组延长(GBM/Astro p=0.075,GBM p=0.030),p53阴性/PIK3R2阴性亚组OS显著改善。结论:PIK3R2阴性及p53阴性免疫染色可预测AFTV治疗疗效和总生存期。

要点

  • AFTV组中PIK3R2阴性患者较对照组生存期延长(GBM p=0.030)。
  • p53阴性/PIK3R2阴性亚组在GBM/Astro及GBM病例中均显示OS显著改善。
  • PIK3R2免疫染色或可作为AFTV治疗疗效预测标志物。

核心结论

  • PIK3R2阴性免疫染色及p53阴性提示接受AFTV治疗的GBM患者生存期延长,可能作为疗效和总生存期的预测指标。

研究设计与样本

  • 回顾性分析58例新诊断IDH野生型GBM或IDH突变型4级星形细胞瘤患者,AFTV组29例接受标准治疗联合AFTV,对照组29例仅接受标准治疗。
  • 对肿瘤组织进行PIK3R2和p53免疫染色,PIK3R2表达以34%为cutoff值分类,评估年龄、性别、手术时KPS及总生存期。

主要发现

  • AFTV组中PIK3R2阴性者较对照组生存期延长:GBM/Astro病例p=0.075,GBM病例p=0.030。
  • 按p53和PIK3R2状态分为四亚组,p53阴性/PIK3R2阴性组在GBM/Astro及GBM病例中均显示OS显著改善。
  • 回归分析显示PD-1与PIK3R2相关性最强。

关键数值与推荐

  • PIK3R2免疫染色表达水平以34%为cutoff值分类为阳性/阴性。
  • AFTV组中PIK3R2阴性者与对照组比较:GBM/Astro病例p=0.075,GBM病例p=0.030。

临床怎么用

  • 对拟接受AFTV治疗的新诊断GBM患者,可检测PIK3R2和p53免疫染色,PIK3R2阴性及p53阴性提示可能从AFTV治疗中获益更多。

局限性

  • 样本量较小(共58例,每组29例),部分生存分析结果p=0.075未达统计学显著性,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults, characterized by high invasiveness and a poor prognosis, with limited treatment options. Our previous study on fractionated radiotherapy, temozolomide, and an autologous formalin-fixed tumor vaccine (AFTV) for newly diagnosed grade 4 astrocytic tumors demonstrated that complete tumor resection and p53 negativity on immunohistochemistry were associated with favorable outcomes. PIK3R2, a key component of the PI3K-Akt signaling pathway, may modulate the host immune response to tumor antigens and influence the efficacy of immunotherapy. In this study, we further investigated whether PIK3R2, a candidate gene identified through gene panel sequencing as potentially associated with prognosis following AFTV treatment, influences patient outcomes after AFTV therapy. METHODS: We analyzed 58 patients with newly diagnosed IDH wildtype GBM or IDH mutant grade 4 astrocytoma (Astro). Among them, 29 received standard treatment combined with AFTV (AFTV group), while 29 underwent standard treatment alone (control group). Immunostaining for PIK3R2 and p53 was performed, and patient characteristics, including age, sex, Karnofsky Performance Status at the time of surgery, and overall survival (OS), were evaluated. PIK3R2 expression levels were classified using a 34% cutoff value. RESULTS: In the AFTV group, survival analysis based on PIK3R2 status (positive/negative) revealed an increased survival in the PIK3R2-negative group when comparing AFTV and control groups (p = 0.075 in GBM/Astro cases and p = 0.030 in GBM cases). When stratifying patients into four subgroups based on p53 and PIK3R2 status (p53-negative/PIK3R2-negative, p53-positive/PIK3R2-positive, p53-negative/PIK3R2-positive, and p53-positive/PIK3R2-negative), a significant improvement in OS was observed in the p53-negative/PIK3R2-negative group both in GBM/Astro cases and GBM cases. PD-1 demonstrated the strongest correlation with PIK3R2 in the regression analysis. CONCLUSION: Negative immunostaining for PIK3R2 as well as negative p53 revealed an increased survival in patients receiving AFTV therapy for GBM. In patients receiving AFTV, these immunostaining results may serve as a predictor of treatment efficacy and overall survival.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Akutagawa K, Miki S, Yamada E, et al. PIK3R2 immunostaining status predicts prognosis in patients with newly diagnosed glioblastoma treated with an autologous tumor vaccine. J Neurooncol. 2025. PMID: 40504311. doi:10.1007/s11060-025-05102-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。